Last 45 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 43.80 | 32.24 | 31.15 | 28.05 | 30.07 | 33.21 | 25.31 | 20.76 | 22.63 | 27.72 | 37.44 | 31.57 | 31.15 | 27.27 | 31.11 | 20.71 | 25.17 | 19.17 | 25.63 | 24.20 | 41.22 |
| — | -2.9% | +23.1% | +35.1% | +32.9% | +19.8% | -32.4% | -34.3% | -27.4% | +1.7% | +20.3% | +52.5% | +23.8% | +42.3% | +21.4% | -14.4% | -38.9% | -47.7% | -38.5% | -32.7% | +58.7% | |
| P/S Ratio | 7.38 | 6.18 | 5.38 | 4.92 | 5.74 | 5.79 | 3.92 | 4.25 | 4.96 | 5.02 | 6.26 | 6.33 | 4.89 | 3.90 | 4.11 | 3.48 | 4.37 | 3.30 | 3.59 | 4.49 | 6.66 |
| — | +6.8% | +37.2% | +15.7% | +15.8% | +15.3% | -37.3% | -32.8% | +1.3% | +28.6% | +52.1% | +81.7% | +12.0% | +18.2% | +14.6% | -22.5% | -34.4% | -36.0% | -40.0% | -24.5% | +31.9% | |
| P/B Ratio | 43.04 | 30.28 | 35.11 | 23.24 | 35.44 | 52.02 | 54.93 | 16.01 | 12.88 | 12.15 | 17.31 | 19.26 | 17.45 | 16.33 | 19.39 | 17.41 | 17.82 | 14.49 | 17.80 | 9.83 | 8.62 |
| — | -41.8% | -36.1% | +45.2% | +175.0% | +328.1% | +217.4% | -16.9% | -26.2% | -25.6% | -10.8% | +10.6% | -2.1% | +12.7% | +8.9% | +77.1% | +106.8% | +113.1% | +127.7% | +36.4% | +32.5% | |
| P/FCF | 27.39 | 22.54 | 27.57 | 23.98 | 21.62 | 14.56 | 16.62 | 20.51 | 14.53 | 19.33 | 31.91 | 21.97 | 16.66 | 18.19 | 25.59 | 21.42 | 13.51 | 12.51 | 14.76 | 40.20 | 33.24 |
| — | +54.8% | +65.9% | +16.9% | +48.8% | -24.7% | -47.9% | -6.6% | -12.8% | +6.2% | +24.7% | +2.5% | +23.3% | +45.4% | +73.4% | -46.7% | -59.4% | -46.1% | -49.7% | +31.9% | +147.9% | |
| EV / EBITDA | 32.74 | 24.91 | 26.53 | 22.53 | 24.97 | 25.42 | 17.94 | 19.07 | 18.99 | 21.25 | 28.55 | 28.50 | 25.59 | 21.08 | 22.78 | 16.97 | 21.40 | 15.90 | 20.47 | 21.67 | 32.67 |
| — | -2.0% | +47.9% | +18.1% | +31.5% | +19.6% | -37.2% | -33.1% | -25.8% | +0.8% | +25.3% | +67.9% | +19.6% | +32.6% | +11.3% | -21.7% | -34.5% | -35.6% | -39.3% | -23.6% | +55.6% | |
| EV / EBIT | 34.46 | 25.09 | 26.38 | 22.66 | 25.54 | 26.49 | 19.21 | 19.44 | 18.85 | 21.43 | 29.04 | 28.07 | 26.96 | 23.22 | 25.09 | 18.00 | 26.14 | 15.92 | 21.52 | 22.99 | 35.23 |
| — | -5.3% | +37.3% | +16.5% | +35.5% | +23.6% | -33.8% | -30.7% | -30.1% | -7.7% | +15.8% | +55.9% | +3.1% | +45.8% | +16.6% | -21.7% | -25.8% | -40.2% | -42.9% | -26.7% | +52.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.1% | 31.3% | 28.5% | 27.8% | 29.0% | 29.8% | 29.8% | 31.9% | 33.2% | 31.7% | 29.1% | 30.4% | 27.4% | 27.0% | 27.0% | 30.0% | 29.4% | 31.0% | 28.2% | 29.8% | 28.5% |
| — | +4.8% | -4.5% | -13.0% | -12.8% | -5.8% | +2.4% | +5.2% | +21.1% | +17.2% | +8.0% | +1.2% | -6.5% | -12.8% | -4.3% | +0.6% | +3.0% | +5.3% | +5.1% | -1.2% | -10.6% | |
| Operating Margin | 21.1% | 23.1% | 20.8% | 20.0% | 21.6% | 21.5% | 20.9% | 20.3% | 23.4% | 21.1% | 19.9% | 20.4% | 17.5% | 17.2% | 17.0% | 19.9% | 19.4% | 20.3% | 17.2% | 19.4% | 17.8% |
| — | +7.6% | -0.9% | -1.5% | -7.4% | +2.1% | +5.2% | -0.2% | +33.4% | +22.1% | +17.1% | +2.5% | -9.7% | -15.0% | -0.8% | +2.4% | +9.1% | +11.6% | +12.4% | +6.0% | -16.0% | |
| Net Margin | 17.8% | 19.2% | 17.2% | 17.5% | 19.1% | 16.8% | 15.0% | 20.5% | 21.8% | 18.1% | 16.7% | 20.1% | 15.7% | 14.3% | 13.3% | 16.8% | 17.4% | 17.2% | 14.1% | 18.5% | 16.2% |
| — | +14.0% | +14.7% | -14.6% | -12.5% | -6.9% | -10.6% | +2.2% | +38.8% | +26.2% | +26.3% | +19.5% | -9.8% | -16.7% | -5.7% | -9.4% | +7.5% | +4.7% | -2.1% | +11.2% | -17.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 70.2% | 27.0% | 23.5% | 23.4% | 35.9% | 47.7% | 23.6% | 16.1% | 13.7% | 11.7% | 12.3% | 16.7% | 15.2% | 16.4% | 16.5% | 19.9% | 18.7% | 20.9% | 11.1% | 7.9% | 5.4% |
| — | -43.4% | -0.2% | +45.1% | +161.9% | +306.9% | +91.4% | -3.1% | -9.8% | -28.4% | -25.6% | -16.1% | -18.5% | -21.5% | +48.8% | +152.5% | +245.0% | +275.7% | +138.1% | +51.3% | -15.1% | |
| ROA | 22.1% | 6.3% | 5.8% | 6.0% | 7.2% | 6.7% | 5.2% | 5.7% | 5.6% | 4.8% | 4.8% | 5.9% | 5.0% | 4.9% | 4.4% | 5.3% | 5.1% | 5.0% | 3.7% | 4.1% | 3.1% |
| — | -5.7% | +11.4% | +5.3% | +29.6% | +38.8% | +9.4% | -3.5% | +12.3% | -1.2% | +9.1% | +12.0% | -2.8% | -2.4% | +17.4% | +30.0% | +65.7% | +56.6% | +35.7% | +33.9% | -18.4% | |
| ROIC | 154.9% | 322.7% | 184.8% | 75.7% | 63.0% | 49.7% | 34.2% | 30.3% | 29.6% | 22.8% | 20.1% | 18.2% | 13.4% | 12.0% | 10.6% | 11.7% | 10.0% | 9.5% | 7.0% | 7.5% | 6.6% |
| — | +549.6% | +441.0% | +149.5% | +112.9% | +117.5% | +70.1% | +66.5% | +120.3% | +91.0% | +88.7% | +55.8% | +34.2% | +25.3% | +51.9% | +56.3% | +52.2% | +48.5% | +39.3% | +34.6% | +5.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.25 | 0.28 | 0.20 | 0.55 | 0.49 | 0.87 | 0.21 | 0.15 | 0.15 | 0.17 | 0.20 | 0.25 | 0.30 | 0.50 | 0.74 | 0.49 | 0.80 | 1.36 | 0.23 | 0.14 |
| — | -49.1% | -68.2% | -4.2% | +256.8% | +236.9% | +403.7% | +5.2% | -39.9% | -52.1% | -65.3% | -72.7% | -48.0% | -61.9% | -63.4% | +217.0% | +255.7% | +458.4% | +925.2% | +76.1% | -3.8% | |
| Debt / EBITDA | 0.44 | 0.85 | 0.86 | 0.82 | 1.56 | 0.97 | 1.12 | 1.05 | 0.95 | 1.07 | 1.17 | 1.23 | 1.51 | 1.56 | 2.29 | 2.80 | 2.29 | 3.34 | 5.85 | 2.04 | 2.17 |
| — | -12.3% | -23.6% | -21.7% | +64.4% | -9.7% | -4.2% | -14.2% | -37.0% | -31.3% | -48.8% | -56.2% | -34.3% | -53.3% | -60.9% | +36.8% | +5.7% | +53.6% | +147.1% | -5.7% | +14.0% | |
| Current Ratio | 0.74 | 0.83 | 0.73 | 0.85 | 0.74 | 0.57 | 0.43 | 0.73 | 0.93 | 0.99 | 0.88 | 0.78 | 0.64 | 0.53 | 0.44 | 0.42 | 0.42 | 0.41 | 0.37 | 0.61 | 1.24 |
| — | +44.9% | +71.5% | +15.7% | -21.0% | -42.1% | -51.4% | -6.0% | +45.2% | +87.4% | +97.6% | +86.8% | +54.4% | +28.6% | +18.8% | -32.1% | -66.5% | -66.8% | -67.9% | -48.5% | +15.2% | |
| Quick Ratio | 0.74 | 0.83 | 0.73 | 0.85 | 0.74 | 0.57 | 0.43 | 0.73 | 0.93 | 0.99 | 0.88 | 0.78 | 0.64 | 0.53 | 0.44 | 0.42 | 0.42 | 0.41 | 0.37 | 0.61 | 1.24 |
| — | +44.9% | +71.5% | +15.7% | -21.0% | -42.1% | -51.4% | -6.0% | +45.2% | +87.4% | +97.6% | +86.8% | +54.4% | +28.6% | +18.8% | -32.1% | -66.5% | -66.8% | -67.9% | -48.5% | +15.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | 793.39 | 56.45 | 100.92 | 81.50 | 52.70 | 114.14 | — | 2432.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MEDP stock.
Medpace Holdings, Inc.'s current P/E is 43.8x. The average P/E over the last 4 quarters is 30.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Medpace Holdings, Inc.'s current operating margin is 21.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Medpace Holdings, Inc.'s business trajectory between earnings reports.